Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group's TQB3454 tablet was included in the priority review list by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.
The drug is indicated for the treatment of patients with locally advanced, recurrent and/or metastatic biliary tract cancer harboring IDH1 mutations.
Hotel Royal (SGX:H12) named Lee Zongye as its group chief executive officer, effective July 7, according to a Thursday filing with the Singapore Exchange.Zongye is currently the company's deputy chief executive officer, the filing said.
Tredlines (SGX:42T) portfolio company, Phytolon, completed a $23.6 million series B financing to commercialize its natural food colors in the U.S., according to a Thursday filing with the Singapore Exchange.The financing round was led by an unnamed strategic investor, with funding structured in three stages.The portfolio company focuses on fermentation-based natural color solutions.
Mitsubishi Materials (TYO:5711) has entered a final agreement to integrate its business related to the purchase of copper concentrates and the sale of related products into Pan Pacific Copper (PPC), a joint venture among JX Advanced Metals (TYO:5016), Mitsui Kinzoku (TYO:5706) and Marubeni (TYO:8002).The integration will be implemented through a two-step absorption-type company split, under which PPC will establish a new wholly owned subsidiary to receive the business, with the transaction scheduled to take effect on Oct. 1, subject to regulatory approvals.Following the integration, Mitsubishi Materials will hold a 32% stake in PPC, and PPC will become an equity-method affiliate of the company, according to a Tokyo bourse filing on Thursday.The company's board of directors resolved to proceed with the integration on May 28, 2026, following a basic agreement announced in November 2025.